Companies / Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

Nasdaq: INTSCIK 1567264SHELTON, CT

Financials

Revenue—
Net income$-11.61M
Total debt—
Cash$9.53M
Diluted EPS$-8.56
Shares outstanding3.3M

Ownership

3.3M shares outstanding · as of Aug 7, 2026
7.1%Insiders
Ownership
Insiders7.12%232,564
Institutions1.56%51,019
Public float91.31%2,981,296

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Bender Lewis HCEOPresident and CEO · Director
3.63%118,549
Wesolowski John MPrincipal Accounting Officer
2.61%85,354
Talamo JosephChief Financial Officer
0.88%28,661

Institutional holders 2

View all →
HolderValue% of shares
Geode Capital Management, LLC$153.0K0.80%
Nano Cap New Millennium Growth Fund L P$147.0K0.77%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 26, 2026Bender Lewis H
CEO
GrantCommon Stock, $0.0001 Par Value$230.6K+38K
+46.72%
118,549
3.63% of shares
low
Dec 31, 2025Talamo Joseph
Executive
GrantCommon Stock, $0.0001 Par Value$3.8K+14K
+102.14%
28,661
0.88% of shares
low
Dec 31, 2025Wesolowski John M
Executive
GrantCommon Stock, $0.0001 Par Value$2.3K+9K
+11.67%
85,354
2.61% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
INTSCommon StockEquity45828J202BBG00B57FZV6